课题基金 / 基金详情

The essential role of miR-27a in craniofacial and body skeletons.

The essential role of miR-27a in craniofacial and body skeletons.
miR-27a 在颅面和身体骨骼中的重要作用。
批准号:
9900768
负责人:
Takamitsu Maruyama
金额:
$16.12万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
已结题
起止时间:
2019-04-01 至 2021-05-31

项目摘要

项目成果

Takamitsu Maruyama的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Title The essential role of miR-27a in craniofacial and body skeletons Abstract MicroRNAs are ~22 nucleotides noncoding RNAs which control gene expression at post-transcriptional levels. Owing to its ability to simultaneously modulate a vast amount of genes, microRNA has been postulated to work as a master regulator for cell type-specific development and function. Although gain-of-function analysis with microRNA overexpression can affect these processes in transgenic mice, loss-of-function study often fails to detect phenotypic alterations and is unable to faithfully determine their role in development and disease. Moreover, results obtained from in vitro analysis sometimes are not supported by functional analyses in vivo. Studies of Dicer, an enzyme essential for biosynthesis of microRNAs, have implicated their importance in bone remodeling. However, the exact miRNA(s) involved has not been identified. The cluster of miR-23a~27a~24-2 consists of three miRNAs generated from a single transcript. Dysregulation of miR-23a and miR-27a has been shown in osteoporosis patients but their regulatory role remains elusive. In cell culture study, high levels of miR-23a or miR-27a inhibits OB differentiation, suggesting that they are negative regulators for bone formation. In mice, OB-specific expression of miR-23a~27a~24-2 cluster reveals its effects on osteocyte but not OB differentiation. The animal study does not support the cell culture analysis. There is an urgent need to develop loss-of-function models to definitively assess the function of these microRNAs in vivo. To fill our knowledge gaps, we created a mouse model deficient for miR-27a using CRSPR-Cas9 gene editing. The loss of this single miRNA causes severe osteoporosis in the craniofacial and body skeletons, suggesting the function of miR-27a cannot be substituted. The bone loss phenotype also becomes more prominent with age. New genetic evidence, indicating miR-27a as a positive regulator in bone remodeling, strongly argues against the previous cell culture study. In this application, we will characterize craniofacial and skeletal defects in miR-27a deficient mice. We will examine osteoblast and osteoclast abnormalities associated with the mutation to cause an imbalance in skeletal remodeling. To further elucidate the mechanism by which miR-27a regulates bone formation and resorption, we will identify its direct targets using unbiased screening. The completion of this proposal has outstanding potential to advance our knowledge base of epigenetic regulation in bone metabolism, leading to novel strategies for prevention and treatment of craniofacial and skeletal disorders.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Identification and Characterization of Endogenous Dental Pulp Stem Cells
  • 批准号:
    10366016
  • 项目类别:
  • 资助金额:
    $24.88万
  • 财政年份:
    2021
  • 负责人:
    Takamitsu Maruyama
  • 依托单位:
Identification and Characterization of Endogenous Dental Pulp Stem Cells
  • 批准号:
    10409267
  • 项目类别:
  • 资助金额:
    $28.32万
  • 财政年份:
    2021
  • 负责人:
    Takamitsu Maruyama
  • 依托单位:
The essential role of miR-27a in craniofacial and body skeletons
  • 批准号:
    10433673
  • 项目类别:
  • 资助金额:
    $4.05万
  • 财政年份:
    2021
  • 负责人:
    Takamitsu Maruyama
  • 依托单位:
Identification and Characterization of Endogenous Dental Pulp Stem Cells
  • 批准号:
    10208616
  • 项目类别:
  • 资助金额:
    $1.19万
  • 财政年份:
    2021
  • 负责人:
    Takamitsu Maruyama
  • 依托单位:
国内基金
海外基金
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
  • 批准号:
    JCZRQN202500010
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
  • 依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
  • 批准号:
    2025JJ70209
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
    雷芬芳
  • 依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
  • 批准号:
    --
  • 项目类别:
    面上项目
  • 资助金额:
    --
  • 批准年份:
    2024
  • 负责人:
    万荣
  • 依托单位: